BioMarin Pharmaceuticals
BMRN
BMRN
551 hedge funds and large institutions have $17.4B invested in BioMarin Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 61 funds opening new positions, 206 increasing their positions, 187 reducing their positions, and 81 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
8% less capital invested
Capital invested by funds: $18.9B → $17.4B (-$1.47B)
25% less first-time investments, than exits
New positions opened: 61 | Existing positions closed: 81
27% less funds holding in top 10
Funds holding in top 10: 15 → 11 (-4)
Holders
551
Holding in Top 10
11
Calls
$238M
Puts
$123M
Top Buyers
| 1 | +$246M | |
| 2 | +$162M | |
| 3 | +$70.2M | |
| 4 |
Primecap Management
Pasadena,
California
|
+$68.7M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$59.7M |
Top Sellers
| 1 | -$395M | |
| 2 | -$322M | |
| 3 | -$101M | |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$95.2M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$74.2M |